Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NAUTILUS: A Phase 1b/2 Study of OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1b) and in Patients With Advanced NRAS-Mutated Melanoma (Phase 2)

Next Previous
X
Search
Trial Profile

NAUTILUS: A Phase 1b/2 Study of OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1b) and in Patients With Advanced NRAS-Mutated Melanoma (Phase 2)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Bocodepsin (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Nautilus
  • Sponsors OnKure Therapeutics

    • Most Recent Events

    • 05 Mar 2024 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2022 According to an OnKure Therapeutics media release, the company plans to initiate the Phase 2 portion of this study.
    • 02 Jun 2022 According to an OnKure Therapeutics media release, first patient has been dosed in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top